Basic Information
| LncRNA/CircRNA Name | GAPLINC |
| Synonyms | NA |
| Region | GRCh38_18:3466250-3478978 |
| Ensemble | ENSG00000266835 |
| Refseq | NR_110429 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | perihilar cholangiocarcinoma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | perihilar cholangiocarcinoma tissues, cell lines(PHCC, QBC939, FRH0201, HIBEpiC) |
| Expression Pattern | up-regulated |
| Function Description | The present study observed a significant upregulation of GAPLINC in PHCC cell lines and clinical specimens. high GAPLINC expression was revealed to be associated with the T stage (P=0.013), N stage (P<0.001) and Tumor-Node-Metastasis stage (P<0.001) of PHCC. GAPLINC expression was associated with poor overall survival and progression-free survival rates in PHCC. PHCC cells with GAPLINC overexpression exhibited markedly increased proliferation ability in a Cell Counting kit-8 assay. |
| Pubmed ID | 30128015 |
| Year | 2018 |
| Title | Upregulation of gastric adenocarcinoma predictive long intergenic non-coding RNA promotes progression and predicts poor prognosis in perihilar cholangiocarcinoma. |
External Links
| Links for GAPLINC | GenBank HGNC NONCODE |
| Links for perihilar cholangiocarcinoma | OMIM COSMIC |